Novo Nordisk, Eli Lilly Face 4,400 GLP-1 Lawsuits Over GI Injuries and Vision Loss
Updated
Updated · The Dallas Express · Jul 9
Novo Nordisk, Eli Lilly Face 4,400 GLP-1 Lawsuits Over GI Injuries and Vision Loss
2 articles · Updated · The Dallas Express · Jul 9
Summary
More than 4,400 lawsuits have been filed against Novo Nordisk and Eli Lilly over GLP-1 drugs, with over 3,800 cases consolidated in federal multidistrict litigation focused mainly on gastrointestinal injuries and vision loss.
Plaintiffs say the companies failed to adequately warn users about risks including gastroparesis, intestinal blockages, pancreatitis, gallbladder problems and NAION, a form of sudden vision loss; both drugmakers deny liability and say the medicines are safe when used as prescribed.
About 75% of sampled claims center on gastroparesis, while at least 110 plaintiffs allege vision loss; bellwether trials are expected in late 2026 or 2027, and no global settlement has been reached.
Roughly 9 million GLP-1 prescriptions had been written by late 2023 after use more than tripled since 2020, as Ozempic, Wegovy and Lilly's drugs expanded from diabetes treatment into a mass weight-loss market.
That boom drove shortages, heavy telehealth and off-label use, and broader debate over long-term safety, access for diabetes patients and the cosmetic culture surrounding rapid weight loss.
With thousands of lawsuits mounting, could the Ozempic craze trigger a multi-billion dollar legal fallout?
As studies link GLP-1 drugs to blindness, what are the hidden long-term costs of this weight-loss revolution?
Are popular weight-loss drugs causing an unforeseen wave of stomach paralysis and permanent vision loss?
GLP-1 Drug Litigation Surges Past 10,000 Cases: Legal, Regulatory, and Patient Impacts in 2026
Overview
As of July 2026, lawsuits against GLP-1 drug manufacturers have surged past 10,000, with projections suggesting over 20,000 cases by year’s end as more patients report severe gastrointestinal injuries. These cases are now consolidated into a single Multidistrict Litigation (MDL) in Louisiana, streamlining the process and helping avoid inconsistent rulings. Plaintiffs claim that manufacturers failed to provide adequate warnings about serious risks. The MDL structure is designed to manage complex discovery and facilitate settlements, making it easier for affected patients to pursue legal action while conserving resources for everyone involved.